SCHEMBL15745111

SCHEMBL15745111

CCOC(=O)CCN(C(=O)c1ccc2[nH]c(CNc3ccc(C(=N)N)cc3)nc2c1)c1ccccn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 2/20 0.71
F2 P00734 14/20 0.57
SLC22A2 O15244 1/20 0.57
F10 P00742 1/20 0.57
PLG P00747 1/20 0.57
PLAT P00750 1/20 0.57
PROC P04070 1/20 0.57
HPN P05981 1/20 0.57
PRSS1 P07477 1/20 0.57
PRSS2 P07478 1/20 0.57
PRSS3 P35030 1/20 0.57
SLC47A2 Q86VL8 1/20 0.57
SLC47A1 Q96FL8 1/20 0.57
NR1I2 O75469 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
SLC6A2 P23975 1/20 0.54
AGTR1 P30556 1/20 0.54
SLC6A3 Q01959 1/20 0.54
SCN5A Q14524 1/20 0.54
KLK1 P06870 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7848412 0.93 NQO2 (0.62) NQO2F2SLC22A2F10PLG
SCHEMBL28473319 0.93 NQO2 (0.62) NQO2F2SLC22A2F10PLG
SCHEMBL15745127 0.91 F2 (0.59) NQO2F2SLC22A2F10PLG
SCHEMBL15745112 0.91 F2 (0.65) NQO2F2SLC22A2F10PLG
SCHEMBL15562470 0.90 NQO2 (0.57) NQO2F2SLC22A2F10PLG
SCHEMBL9901594 0.87 NQO2 (0.60) NQO2F2SLC22A2F10PLG
Hydrochloric Acid SCHEMBL9902965 0.87 NQO2 (0.59) NQO2F2SLC22A2F10PLG
SCHEMBL15745130 0.86 F2 (0.75) NQO2F2SLC22A2F10PLG
SCHEMBL15745151 0.86 F2 (0.75) NQO2F2SLC22A2F10PLG
SCHEMBL17517891 0.86 F2 (0.75) NQO2F2SLC22A2F10PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006448-B2 Process for the preparation of benzimidazole derivatives and its salts MSN LABORATORIES PRIVATE LIMITED (IN) 2015-04-14 US disclosed
US-9006448-B2 Process for the preparation of benzimidazole derivatives and its salts MSN LABORATORIES PRIVATE LIMITED (IN) 2015-04-14 US disclosed
US-20140148601-A1 PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND ITS SALTS MSN LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
US-20140148601-A1 PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND ITS SALTS MSN LABORATORIES LIMITED (IN) 2014-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148601-A1 PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND ITS SALTS CYP2B6, CYP2D6, CYP3A4 NQO2 743/4885F2 40/4885SLC22A2 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.